Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion .
Burning Rock Biotech LimitedAugust 3, 2021 GMT
GUANGZHOU, China, Aug. 03, 2021 (GLOBE NEWSWIRE) Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of synthetic lethality. The two companies will jointly develop CDx for a targeted oncology drug, Senaparib (IMP4297), a PARP inhibitor, for the treatment of prostate cancer globally, including CDx submissions to both the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration of China (NMPA). The global program will be supported by Burning Rock’s Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Patho
Benzinga s Top Ratings Upgrades, Downgrades For July 14, 2021 benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Baillie Gifford China Growth targets ‘exciting’ pipeline of private companies
‘If you’re not looking for growth companies in China, you’re missing the point,’ says Sophie Earnshaw
Baillie Gifford China Growth trust manager Sophie Earnshaw is eyeing an “exciting” pipeline of private companies in China, while also playing up themes like the Gen Z consumer and healthcare innovation.
Since Earnshaw (pictured) and co-manager Roderick Snell took over the trust from Witan last September, it has undergone a radical transformation.
In addition to focusing solely on China as opposed to the broader Asia Pacific region, the trust invests in a slimmer number of 40-80 holdings, representing companies the managers believe will deliver “outstanding growth” in the next five to 10 years.